Last updated on December 2016

Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease

Brief description of study

A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.

Detailed Study Description

Men and women from 60 to 85 years old with diagnosis of mild severity Alzheimer's disease, according to the diagnostic criteria established by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA).

Clinical Study Identifier: NCT02991235

Find a site near you

Start Over

Fundaci ACE

Barcelona, Spain
  Connect »